Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Equillium ( (EQ) ).
On September 30, 2025, Equillium announced significant changes in its board and executive structure. Stephen Connelly, Ph.D., and Bala Manian, Ph.D., resigned from the board, effective October 1, 2025, leading to a reduction in board size from nine to seven members. Charles McDermott and Mark Pruzanski, M.D., were appointed to key committee roles, and Daniel M. Bradbury transitioned to Chairman of the Board. Dr. Connelly was appointed as the company’s President, while Bruce Steel continued as CEO. Simultaneously, Equillium terminated its collaboration and license agreements with Biocon Limited, with all licenses, including those for itolizumab, reverting to Biocon. Equillium will receive a technical service fee of $363,000 from Biocon, offset against amounts owed by Equillium.
The most recent analyst rating on (EQ) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Equillium stock, see the EQ Stock Forecast page.
Spark’s Take on EQ Stock
According to Spark, TipRanks’ AI Analyst, EQ is a Neutral.
Equillium’s overall score is driven by positive corporate events and strong technical momentum. However, financial performance and valuation concerns, including ongoing losses and operational inefficiencies, weigh down the score.
To see Spark’s full report on EQ stock, click here.
More about Equillium
Average Trading Volume: 7,998,352
Technical Sentiment Signal: Buy
Current Market Cap: $79.14M
For an in-depth examination of EQ stock, go to TipRanks’ Overview page.